试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
编号:NCT05239663登记状态:提前终止企业 / 申办者:Sun Yat-sen University
药物 / 成分:Ganglioside-Monosialic Acid、250ml normal saline (NS)
登记的停止原因(原文):Difficulty accruing subjects the study accrual was closed
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
编号:NCT05579977登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:PF-07081532、Placebo、Rybelsus
登记的停止原因(原文):The decision to terminate clinical development of PF-07081532 is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
编号:NCT05764915登记状态:提前终止企业 / 申办者:Regor Pharmaceuticals Inc.
药物 / 成分:RGT-264 phosphate tablets
登记的停止原因(原文):Due to the change in study plan and not due to safety reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
编号:NCT05908396登记状态:提前终止企业 / 申办者:IGM Biosciences, Inc.
药物 / 成分:IGM-2644
登记的停止原因(原文):Company Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-01
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
编号:NCT05965505登记状态:提前终止企业 / 申办者:Axter Therapeutics (Beijing) Co., Ltd
药物 / 成分:AXT-1003
登记的停止原因(原文):Due to the adjustment of the protocol and expansion of the indication population, a new clinical trial protocol was submitted to the Health Authority, so the registration was conducted as a new clinical trial and this trial was terminated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-31
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
编号:NCT01296555登记状态:提前终止企业 / 申办者:Genentech, Inc.
药物 / 成分:Fulvestrant、GDC-0032、Letrozole、Midazolam
登记的停止原因(原文):The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-31
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
编号:NCT02520427登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:AMG 330
登记的停止原因(原文):Amgen strategic business decision to cancel following portfolio review, re-prioritization.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-31
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
编号:NCT02707666登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:Pembrolizumab、Cisplatin and Pemetrexed
登记的停止原因(原文):unable to complete enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-31
Tipifarnib in Subjects With Myelodysplastic Syndromes
编号:NCT02779777登记状态:提前终止企业 / 申办者:Kura Oncology, Inc.
药物 / 成分:Tipifarnib
登记的停止原因(原文):Lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-07-31
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
编号:NCT03323398登记状态:提前终止企业 / 申办者:ModernaTX, Inc.
药物 / 成分:mRNA-2416、Durvalumab
登记的停止原因(原文):This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.
查看官方原始记录 ↗